Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
OBI Pharma Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, showing a lack of concentration in the current prosecution pipeline. With 2 pending office actions being handled by different individuals, the company must manage multiple sets of examiner preferences simultaneously.
The involvement of 2 distinct art units indicates that the active matters fall into different technical sub-categories within the Biotechnology & Pharmaceuticals field. This diversity suggests that the company is pursuing intellectual property across varied applications, rather than focusing on a niche that would be contained within a single art unit. Each of the 2 distinct art units will likely apply different sets of prior art and examination standards.
The busiest examiner for this portfolio, RODRIGUEZ-GARCIA, VALERIE, is currently overseeing 1 pending office action. Since there are 2 pending office actions in total, this busiest examiner is responsible for a portion of the active workload. This distribution ensures that no single examiner has a majority influence over the company's current patenting efforts, as the 2 pending office actions are split between RODRIGUEZ-GARCIA, VALERIE and another distinct examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 66.7% | +40.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288215 | COMBINATION THERAPY BY USING AKR1C3-ACTIVATED COMPOUND WITH IMMUNE CHECKPOINT INHIBITOR | RODRIGUEZ-GARCIA, VALERIE | — |
| 18259277 | GLOBO SERIES ANTIGENS-BINDING CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | YOUTCHOM PENDIE, EMMANUEL LED | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288215 | COMBINATION THERAPY BY USING AKR1C3-ACTIVATED COMPOUND WITH IMMUNE CHECKPOINT INHIBITOR | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Final Rejection | — | Pending | Oct 25, 2023 |
| 18259277 | GLOBO SERIES ANTIGENS-BINDING CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | §103 | Non-Final OA | — | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial